InVivo Therapeutics Holdings Corp., has announced that former Stryker Spine, Inc. executive Robert Housler Jr., will be joining the company as the Vice President of Business Development.
Massachussetts based InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralysed as a result of traumatic spinal cord injury. InVivo is currently extending the Company’s pipeline beyond spinal cord injury treatments into a wide range of applications, including the estimated $22 billion annual market for chronic peripheral nerve pain.
As Vice President of Business Development, Mr. Housler will lead InVivo’s effort to establish strategic relationships and partnerships including targeted licensing of InVivo’s technologies to neurotrauma industry leaders.
With over 20 years pertinent industry experience, Mr. Housler spent the last five years at Stryker Spine as Director of Strategic Sales, and also led global Medical Education efforts. While at Stryker, he created a business development strategy to grow domestic sales to $440 million. During his time at Stryker he advanced through the ranks, rising to regional, national and international executive sales positions. Housler received his MBA at the State University of New York at Buffalo.
InVivo Chief Executive Officer Frank Reynolds said, “Bob’s successes in leading and executing a business development strategy in the medical device industry, specifically focusing on the spine, will help us to drive rapid growth and adoption of InVivo’s products. With a clear HDE pathway, we believe that we’ll quickly advance our scaffolding device and other technologies to commercialization while generating revenue through partnerships in the near-term.”
Robert Housler comments
“InVivo’s scientific team and awards speak for themselves, and I’ve been impressed with the recent developments InVivo has made to prepare for commercialization,” said Mr. Housler. “As the company comes closer to achieving FDA approval to begin human trials, the HDE approval process will provide us with an expedited path to revenue, and we need to be prepared to meet market needs. In addition, applications outside of the spinal cord will require partnerships for development and I look forward to putting these agreements into place as soon as possible. I am honored to join the team to help make these technologies a success.”
Source: InVivo Therapeutics Holdings Inc.